Home » Pharma News (page 4)

Pharma News

Cipla divests 16.7 per cent stake in Chase Pharma to Allergan

Cipla divests 16.7 per cent stake in Chase Pharma to Allergan Drug major CiplaBSE 0.45 % today said Chase Pharmaceuticals Corporation, in which it has 16.7 per cent stake has been acquired by Ireland-headquartered Allergan plc. Delaware-based Chase Pharmaceuticals Corporation, in which the company’s UK arm Cipla (EU) Ltd has 16.7 per cent stake, has been acquired by a subsidiary ... Read More »

Zydus Cadila gets USFDA nod for anti-infections tablets

Zydus Cadila gets USFDA nod for anti-infections tablets NEW DELHI: Drug firm Zydus Cadila has received final approval from the US health regulator to market its Metronidazole tablets used for the treatment of infections caused by bacteria or parasites. The company has received “final approval from the United States Food and Drug Administration (USFDA) to market Metronidazole tablets USP in ... Read More »

Pharma city to be connected with MMT

 Pharma city to be connected with MMTS Hyderabad: Industries and municipal administration minister KT Rama Rao said the upcoming Pharma City on the outskirts of the city will be connected with a multi-modal transit system apart from linking Outer Ring Road, the proposed Regional Ring Road and National and state highways. These would be incorporated in the master plan for ... Read More »

For skull surgery Chinese doctors use 3D printer

For skull surgery Chinese doctors use 3D printer  BEIJING: Chinese doctors have successfully replaced a section of a woman cancer patient’s forehead with a 3D-printed part. The patient who is in her early 20s had recurrent tumours for over 16 years and had kept her hair long at the front to cover the growths. “I have had bangs for over ... Read More »

GSK presents new data backing shingles vaccine

GSK presents new data backing shingles vaccine The firm says data show that when Shingrix was given to patients aged 50 years or over at the same time as an unadjuvanted seasonal flu vaccine, both vaccines were well tolerated and the immune response to each vaccine was similar whether it was administered at the same time or separately. On the ... Read More »

Bristol Opdivo discount in kidney cancer changes minds at NICE

Bristol Opdivo discount in kidney cancer changes minds at NICE In July, England’s cost watchdogs weren’t keen on covering Bristol-Myers Squibb’s Opdivo for kidney cancer patients. But the New Jersey drugmaker has said the magic word: discount. Friday, the National Institute for Health and Care Excellence announced a flip-flop on the idea, backing the med for NHS use in previously ... Read More »

Our Culture

Our Culture At VIVAN, our performance-oriented culture and responsible approach are the foundations of our success. We recognize that our business depends on the creativity, innovation, dedication and performance of our Associates. We encourage our Associates to focus on achievements through collaboration, innovation and team work. We support our Associates to take freedom with responsibility, which eventually guides them to ... Read More »

Pharma cos may report low key performance in Q2 FY17

Pharma cos may report low key performance in Q2 FY17   Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said. “We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in ... Read More »

Gilead (GILD) Should Buy This Company

Gilead (GILD) Should Buy This Company The investment bank Evercore ISI surveyed 244 biotech industry observers. The primary goal was for them to identify the biotech company they thought mostly likely to be acquired in the next year and who they thought should buy it. Incyte (INCY) was the top pick for an acquisition target, and Gilead Sciences (GILD) won out ... Read More »

Pfizer’s Sutent comes up big in adjuvant kidney cancer trial

Pfizer’s Sutent comes up big in adjuvant kidney cancer trial COPENHAGEN, Denmark–Pfizer’s kidney-cancer fighter Sutent is an aging drug–but it may just have one more label expansion up its sleeve. Among patients with localized kidney cancer that’s been surgically removed–a group considered high-risk for relapse–the med bested placebo in a Phase III study at improving disease-free survival, the New York pharma ... Read More »

BIGTheme.net • Free Website Templates - Downlaod Full Themes